Literature DB >> 9669393

Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.

A Dimitrakopoulou-Strauss1, L G Strauss, P Schlag, P Hohenberger, M Möhler, F Oberdorfer, G van Kaick.   

Abstract

UNLABELLED: Prediction of chemotherapy response is still a problem in oncological patients.
METHODS: Studies with PET and 18F-fluorouracil (FU) were used for measurements of drug concentrations in patients with liver metastases from colorectal carcinoma. The PET data obtained before onset of FU chemotherapy were correlated to the growth rate of the metastases after therapy. The final evaluation included 25 metastases obtained in 17 patients. CT preceded the first chemotherapeutic cycle and was repeated within 3-11 mo after onset of treatment. The uptake of the cytostatic agent was evaluated in the liver metastases using the SUV at 120 min after tracer infusion. Tumor growth rate of the metastases was calculated based on CT volumetric data.
RESULTS: The trapping of 18F-FU was highly variable even for multiple metastases in the same patients. Six metastases with high 18F-FU uptake values exceeding 3.0 SUV correlated with negative growth rate values, 5 of 25 metastases with intermediate uptake values ranging from 2.0-3.0 SUV were associated with almost stable growth rate values nearly zero and 14 of 25 metastases with low uptake values <2.0 SUV demonstrated positive growth rate values. Only metastases with a 18F-FU uptake exceeding 3.0 SUV at 120 min postinjection demonstrated a response to therapy. A significant correlation of 0.86 (p < 0.001) was found between the 18F-FU uptake values in the metastases measured before chemotherapy and the growth rate of the lesions after treatment.
CONCLUSION: The data show, that FU chemotherapy outcome can be predicted using a single PET study with 18F-FU before onset to therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669393

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.

Authors:  David A Mankoff; Finbarr O'Sullivan; William E Barlow; Kenneth A Krohn
Journal:  Acad Radiol       Date:  2007-04       Impact factor: 3.173

3.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

Review 4.  The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).

Authors:  Tanvi Vaidya; Archi Agrawal; Shivani Mahajan; Meenakshi H Thakur; Abhishek Mahajan
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 5.  Development of Companion Diagnostics.

Authors:  David A Mankoff; Christine E Edmonds; Michael D Farwell; Daniel A Pryma
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

Review 6.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

7.  Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats.

Authors:  Adam L Kesner; Wei-Ann Hsueh; Johannes Czernin; Henry Padgett; Michael E Phelps; Daniel H S Silverman
Journal:  Mol Imaging Biol       Date:  2008-08-05       Impact factor: 3.488

8.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

Authors:  B Böhm; M Voth; J Geoghegan; H Hellfritzsch; A Petrovich; J Scheele; D Gottschild
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-06       Impact factor: 4.553

Review 9.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

Review 10.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.